EE200200127A - Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda - Google Patents

Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda

Info

Publication number
EE200200127A
EE200200127A EEP200200127A EEP200200127A EE200200127A EE 200200127 A EE200200127 A EE 200200127A EE P200200127 A EEP200200127 A EE P200200127A EE P200200127 A EEP200200127 A EE P200200127A EE 200200127 A EE200200127 A EE 200200127A
Authority
EE
Estonia
Prior art keywords
cationic liposomes
taxanes
delivering
blood vessels
angiogenic blood
Prior art date
Application number
EEP200200127A
Other languages
English (en)
Estonian (et)
Inventor
M. Mcdonald Donald
W. Mclean John
Gavin Thurston O.
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of EE200200127A publication Critical patent/EE200200127A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EEP200200127A 1999-09-09 2000-09-08 Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda EE200200127A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39297699A 1999-09-09 1999-09-09
PCT/US2000/024579 WO2001017508A1 (en) 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels

Publications (1)

Publication Number Publication Date
EE200200127A true EE200200127A (et) 2003-04-15

Family

ID=23552795

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200127A EE200200127A (et) 1999-09-09 2000-09-08 Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda

Country Status (21)

Country Link
US (1) US20100226970A1 (pt)
EP (1) EP1210065B1 (pt)
JP (2) JP4848113B2 (pt)
KR (1) KR100591767B1 (pt)
CN (1) CN1235567C (pt)
AT (1) ATE324867T1 (pt)
AU (1) AU782714B2 (pt)
BR (1) BR0013866A (pt)
CA (1) CA2383412C (pt)
CZ (1) CZ2002850A3 (pt)
DE (1) DE60027730T2 (pt)
EA (1) EA005923B1 (pt)
EE (1) EE200200127A (pt)
ES (1) ES2258471T3 (pt)
HK (1) HK1046506B (pt)
HU (1) HUP0202669A3 (pt)
IL (2) IL148372A0 (pt)
MX (1) MXPA02002579A (pt)
PL (1) PL203128B1 (pt)
WO (1) WO2001017508A1 (pt)
ZA (1) ZA200201555B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366025A1 (en) * 2000-05-03 2005-01-24 Munich Biotech Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
ATE345775T1 (de) * 2001-10-03 2006-12-15 Celator Pharmaceuticals Inc Zusammensetzungen zur verabreichung von arzneimittelkombinationen
ES2330326T3 (es) 2002-05-24 2009-12-09 Angiotech International Ag Composiciones y metodos para recubrir implantes medicos.
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
AU2004283464B8 (en) * 2003-10-15 2011-04-14 Syncore Biotechnology Co., Ltd Method of administering cationic liposomes comprising an active drug
JP2007517874A (ja) * 2004-01-16 2007-07-05 バーンズ−ジューイッシュ ホスピタル 標的化アテローム性動脈硬化症治療法
AU2006243337B2 (en) * 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
ES2609388T3 (es) 2006-03-22 2017-04-20 Syncore Biotechnology Co., Ltd Tratamiento del cáncer de mama triple negativo a receptores
ES2447465T3 (es) 2008-03-05 2014-03-12 Baxter International Inc. Partículas de superficie modificada y métodos para la administración dirigida de fármacos
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9706903B2 (en) 2009-06-18 2017-07-18 Endochoice, Inc. Multiple viewing elements endoscope system with modular imaging units
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
KR102653436B1 (ko) * 2016-10-28 2024-03-29 르 라보레또레 쎄르비에르 암의 치료에서 사용하기 위한 리포솜 제형
KR102250123B1 (ko) 2019-11-25 2021-05-10 주식회사 현대케피코 무단 변속기의 제한 목표 기어비 학습 방법
KR102261482B1 (ko) 2019-12-10 2021-06-07 주식회사 현대케피코 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1993018751A1 (en) * 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
SI0703909T1 (en) * 1993-06-11 2000-08-31 Pharmacia & Upjohn Company Delta 6,7 -taxols antineoplastic use and pharmaceutical compositions containing them
JP4850985B2 (ja) * 1993-07-29 2012-01-11 アメリカ合衆国 微小管安定化剤を用いたアテローム性動脈硬化症または再狭窄症の治療方法
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
AU735900B2 (en) * 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2000047235A2 (en) * 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
WO2003037337A1 (en) * 2001-10-30 2003-05-08 Novartis Ag Depot formulations of iloperidone and a star polymer

Also Published As

Publication number Publication date
CN1378443A (zh) 2002-11-06
ZA200201555B (en) 2003-04-30
CZ2002850A3 (cs) 2003-04-16
CA2383412A1 (en) 2001-03-15
WO2001017508A1 (en) 2001-03-15
EA200200229A1 (ru) 2003-06-26
HUP0202669A3 (en) 2004-06-28
KR100591767B1 (ko) 2006-06-23
EP1210065B1 (en) 2006-05-03
KR20030038530A (ko) 2003-05-16
AU7122900A (en) 2001-04-10
EA005923B1 (ru) 2005-08-25
MXPA02002579A (es) 2003-10-14
JP4848113B2 (ja) 2011-12-28
CN1235567C (zh) 2006-01-11
DE60027730D1 (de) 2006-06-08
WO2001017508A9 (en) 2002-10-03
ATE324867T1 (de) 2006-06-15
IL148372A0 (en) 2002-09-12
IL148372A (en) 2007-09-20
HUP0202669A2 (hu) 2004-05-28
PL203128B1 (pl) 2009-08-31
US20100226970A1 (en) 2010-09-09
HK1046506A1 (en) 2003-01-17
DE60027730T2 (de) 2007-03-29
EP1210065A4 (en) 2004-04-28
JP2010280667A (ja) 2010-12-16
HK1046506B (zh) 2006-08-25
EP1210065A1 (en) 2002-06-05
JP2003514768A (ja) 2003-04-22
AU782714B2 (en) 2005-08-25
ES2258471T3 (es) 2006-09-01
BR0013866A (pt) 2002-05-14
PL354721A1 (en) 2004-02-09
CA2383412C (en) 2010-02-02

Similar Documents

Publication Publication Date Title
EE200200127A (et) Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda
NO994413L (no) Kationiske lipidblandinger mÕlsökende angiogene endotelceller
Rondon et al. Hypoxia up-regulates the activity of a novel erythropoietin mRNA binding protein.
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
Sugahara et al. The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
DE60038011D1 (de) Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
GB9817662D0 (en) Substance delivery
WO2006021894A3 (en) Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
SI2089433T1 (sl) Terapevtsko ciljan katepsin s
DE69130569D1 (de) Mit psoralen konjugierte methylphosphonat-oligonukleotide als therapeutische wirkstoffe für chronische myologene leukämie
CN203360445U (zh) 超声微泡介导转染辅助装置
BR0009064A (pt) Plantas apresentando capacidade reprodutiva modificada
NZ516777A (en) Method for delivery of therapeutic agents, particularly nucleic acids, using a solution of dextrin
DE60035687D1 (de) Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen
DE60138762D1 (de) Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren
ITMI931082A1 (it) Coniugati di farmaci antivirali ad attivita' epatotropica, relativi veicolanti e composizioni farmaceutiche che li contengono
TH72418A (th) แทรป vegf และการใช้ทางการบำบัดของมัน
Carcamo Transcription from non-TATA containing promoters: Analysis of the Ad-IVa2 promoter.
Zychlinsky Necrosis and apoptosis: Cell death in the immune system.
Pike et al. Genetic jottings
IT246835Y1 (it) Struttura di supporto per contenitori particolarmente di prodotti incarta , in foglio e simili
EP1849480A3 (en) Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
NO985306L (no) Etenholdige oppl÷sninger og anvendelse derav i metoder for terapi eller pro
AR026246A1 (es) Proteinas hcv reversibles redox con conformacion de tipo nativo